US Patent Issued to Regeneron Pharmaceuticals, University of Maryland, Baltimore on Dec. 30 for "Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors" (Maryland, New York Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,687, issued on Dec. 30, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) and University of Maryland, Baltimore (Baltimore).

"Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors" was invented by Da-Wei Gong (Baltimore), Nehal Gosalia (Tarrytown, N.Y.), Alan Shuldiner (Tarrytown, N.Y.), Cristopher Van Hout (Tarrytown, N.Y.) and James Perry (Baltimore).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, meth...